palmitoylethanolamide.com.au
HomeResearchAssogna 2022

Synaptic Effects of Palmitoylethanolamide in Neurodegenerative Disorders

Assogna M, Di Lorenzo F, Martorana A, Koch G. Biomolecules, 2022; 12(8):1161.

ReviewHumansOther animalsWith luteolin

This study tested palmitoylethanolamide together with luteolin. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.

Design
Review
What was measured
How palmitoylethanolamide, alone and with luteolin, may act on nerve cell connections and brain inflammation in Alzheimer's disease, frontotemporal dementia and motor neurone disease.

What the authors reported

Actions through PPAR-alpha, GPR55 and TRPV1 are described, alongside early clinical signs of effect on cortical plasticity in frontotemporal dementia. The authors say larger trials are needed, and that no clinical data had been published in Alzheimer's disease at the time.

Limits of this study

A narrative review by the group that later ran the frontotemporal dementia trial in this database (Assogna 2025). It was funded by the Italian Ministry of Health, and the authors declared no conflicts.

Source

doi:10.3390/biom12081161

Entry checked against the full text at the publisher (MDPI) on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.